Sign In
Buy DCPH
$25.59
+0 (+0%)
At Close: Sep 09, 2024
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
12:03pm, Friday, 30'th Sep 2022
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Concern
03:02pm, Tuesday, 30'th Aug 2022
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q2 2022 Results - Earnings Call Transcript
07:21am, Sunday, 07'th Aug 2022
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Jennifer Larson - Senior Vice President, Finance and Investor Relations S
Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues
10:32am, Friday, 05'th Aug 2022
Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.
Has Deciphera Pharmaceuticals (DCPH) Outpaced Other Medical Stocks This Year?
10:54am, Wednesday, 06'th Jul 2022
Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why
12:20pm, Wednesday, 15'th Jun 2022
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q1 2022 Results - Earnings Call Transcript
05:22am, Sunday, 08'th May 2022
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Margarida Duarte - SVP & Head, International Steven Hoerter - President, CEO
Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss
03:02pm, Friday, 06'th May 2022 Zacks Investment Research
Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y
03:01pm, Friday, 06'th May 2022 Zacks Investment Research
Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked
02:37pm, Friday, 06'th May 2022 Zacks Investment Research
Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.
Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss
12:02pm, Friday, 06'th May 2022
Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics
03:30pm, Thursday, 05'th May 2022 Zacks Investment Research
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
06:21pm, Wednesday, 04'th May 2022 Zacks Investment Research
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates
12:25pm, Wednesday, 04'th May 2022 Zacks Investment Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 4.76% and 7.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates
09:47am, Wednesday, 04'th May 2022
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 4.76% and 7.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
